Merchavia Holdings 2025: CDX’s FDA win changed the story, but not the parent’s cash reality

Company Overview

Merchavia is not an operating biotech company. It is a tiny listed holding company that owns minority stakes in several life-sciences and MedTech names and tries to create value through future revaluations, commercialization milestones, and, to a limited extent, local distribution activity. That means the first analytical question is not whether one of its portfolio companies has an interesting technology. The first question is whether the parent company can fund itself long enough for one of those assets to turn into real, upstream cash.

What is working now is clear enough. The main asset, CDX, received FDA PMA approval for IsoPSA in November 2025. That is a real de-risking event. It moves CDX from a story built mainly around regulatory expectation to one with an actual commercial regulatory anchor. The problem is that this improvement happened at the asset level, not at the parent-company cash level.

At the parent, the picture remained tight. At year-end 2025 Merchavia had just ILS 352 thousand of cash and cash equivalents plus ILS 50 thousand of restricted deposits. Against that, it had ILS 2.456 million of current liabilities, negative working capital, and an explicit going concern note. That is the core issue. The FDA approval improved the quality of the portfolio, but it did not solve the parent’s funding problem.

A superficial read can also go wrong in another way. The investor presentation highlights four portfolio companies and aggregate last-round valuations of $259 million. But the same slide explicitly says this does not represent Merchavia’s pro-rata share and does not represent NAV. In the actual financial statements, the entire portfolio was carried at only ILS 15.1 million at the end of 2025, and roughly ILS 12.1 million of that came from CDX alone. In other words, more than 80% of the carrying value now sits in one asset. This is no longer a diversified portfolio story. It is a fragile listed parent with one dominant option and a few smaller ones around it.

The Real Economic Map

Events And Triggers

The first trigger: CDX received FDA PMA approval on November 28, 2025 for IsoPSA, a blood test intended to support the biopsy decision for men aged 50 and older with elevated PSA. This is not a cosmetic milestone. According to the report, CDX plans during 2026 to move gradually from a pure LDT model, meaning tests run only in its own lab, toward a broader commercialization model that includes marketing and distributing IVD kits to clinical labs in the US. The company also already has Medicare reimbursement at $760 per test, 39 separate health plans, and coverage across roughly 142 million covered lives. So CDX is now moving from a regulatory story toward an adoption story.

The second trigger: While CDX improved, Merchavia itself again had to lean on its controlling shareholder. In September 2025 the parent received a $233 thousand loan at 4% annual interest, and the company itself concluded that the rate was below market, estimating a market rate of about 6.15%. In February 2026 it approved a broader unsecured credit facility of up to $600 thousand for two years. That helps near-term flexibility, but one detail matters a lot: the controlling shareholder may, but is not obligated to, provide each draw, and every draw requires prior written approval. This is a partial bridge, not fully committed capital already sitting on the balance sheet.

The third trigger: The company also has a possible cash recovery path from an old loan to a third party. In January 2026 it reported that court approval and cooperative approval had been received for the sale of a Kfar Baruch property for net consideration of about ILS 3.35 million. But Merchavia also states that the property is not pledged in its favor, that its rights arise from creditor status within the legal process, and that it cannot reliably estimate the final net proceeds or timing. So this is a possible positive, but not a funding base the parent can budget against.

The fourth trigger: 2025 again showed how Merchavia survives. It posted negative operating cash flow of ILS 1.456 million, negative investing cash flow of ILS 2.477 million, and only because financing cash flow was positive by ILS 2.903 million did it end the year with ILS 352 thousand of cash. The point is simple: until a portfolio asset starts sending real money upward, Merchavia’s survival model still depends on the capital market and related-party financing.

Efficiency, Profitability, And Competitive Position

At Merchavia, profitability is misleading if read like a normal operating company. The parent barely generates meaningful recurring operating income, so the quality of the year is really about two things: whether the parent controls its own expense base, and whether asset values hold or fall. In 2025 the first point improved somewhat, while the second clearly deteriorated.

What Really Drove The Year

Total income fell to ILS 415 thousand from ILS 1.945 million in 2024. That sounds dramatic, but the base matters. In 2024 the company benefited from a ILS 1.5 million reversal of impairment on an old loan, which flattered the comparison. In 2025, other income was just ILS 346 thousand, including ILS 209 thousand from kit sales and ILS 120 thousand from management and strategic advisory services. In other words, the parent’s real operating income base remains extremely small.

On the cost side, general and administrative expense fell to ILS 1.915 million from ILS 2.83 million. That reflects a leaner parent and lower share-based compensation than in the prior year. That is a real positive, but it is not enough. Once a few hundred thousand shekels of income sit against nearly ILS 2 million of parent costs, the company is still nowhere near self-funding.

What ultimately determined the year was portfolio revaluation. Fair-value losses on portfolio investments reached ILS 8.466 million, versus ILS 6.025 million in 2024. That is where the real economic story sits. CDX was relatively stable at the carrying-value level, but CardiacSense, EFA, and Nervio were all marked down sharply. So even if management continues to present a portfolio with several growth engines, the actual economics of 2025 made Merchavia more dependent on CDX and less protected by the rest of the portfolio.

The Portfolio Is No Longer Diversified In Practice

The single most important figure in the report is not the net loss. It is the new composition of the portfolio. CDX slipped only slightly in the books to ILS 12.138 million from ILS 12.557 million, with a small revaluation gain largely offset by FX impact. CardiacSense fell from ILS 4.96 million to ILS 1.471 million, EFA from ILS 2.181 million to ILS 1.033 million, and Nervio from ILS 1.423 million to ILS 456 thousand. That is not just a collection of numbers. It tells you the diversification cushion has been eroded.

That leads to a key conclusion. Even if Merchavia still describes four portfolio companies, it does not really have four symmetrical engines anymore. It has one asset that genuinely advanced on the regulatory-commercial path, and three smaller options, some of which went through a severe value reset. So any reading of Merchavia as a “diversified private portfolio” misses the central point: the stock is now mostly a CDX commercialization option plus a parent-funding risk.

What Is Actually Working

CDX is the reason the story did not break altogether. The PMA approval, the expanding reimbursement base, and the shift toward IVD kit distribution create a clearer economic path than Merchavia has had before. CardiacSense is not all bad either: the company continues to reference strategic commercialization discussions, reduced headcount to lower burn, and receives payments under an engineering collaboration with a global semiconductor company. But this is exactly where value-creation discipline matters. An interesting business signal is not the same thing as accessible value for Merchavia shareholders. Until there is a real commercial deal, monetization event, or healthier financing path, none of that solves the parent’s cash problem.

Cash Flow, Debt, And Capital Structure

For Merchavia, the right framing is all-in cash flexibility, not a theoretical normalized cash bridge. The reason is simple: the critical issue is how much cash the parent actually has left after everything it needs to pay and invest. In 2025, not much was left.

Operating cash flow was negative by ILS 1.456 million. Investing cash flow was negative by another ILS 2.477 million, mainly due to investments of ILS 1.21 million in CardiacSense, ILS 1.105 million in CDX, and ILS 128 thousand in EFA. Against that, financing cash flow of ILS 2.903 million kept the company alive, including ILS 2.133 million from equity issuance and ILS 770 thousand from a controlling-shareholder loan. Put simply, without capital raises and controlling-shareholder funding, Merchavia would not have finished 2025 with positive cash.

The liability structure also matters. The company has no long-term debt, but that is not necessarily a strength. All liabilities are current, and they reached ILS 2.456 million at year-end. That includes a controlling-shareholder loan of ILS 751 thousand, alongside suppliers and other payables. The company also notes that some accrued payables include compensation not temporarily drawn by the CEO and chairman, totaling roughly ILS 683 thousand, with both having committed not to demand repayment while they remain in their roles or until the company has raised capital or secured at least 12 months of funding visibility. That helps, but it also highlights how tight the situation really is.

The controlling-shareholder loan and facility improve the short-term bridge, but they also reveal the real credit picture. Merchavia itself concluded that the September 2025 loan carried a 4% rate that was below market, and that a market rate would have been around 6.15%. So not only is the company dependent on related-party funding, it is receiving terms that it likely would not get from an independent lender. That is an important warning sign. The problem here is not just the price of debt. It is that the truly available funding source is not internal cash generation and not commercial bank credit, but shareholder support and repeated equity issuance.

On the other side, the company carries a loan receivable of ILS 2 million on the balance sheet, with enforcement-related debt of about ILS 6.5 million and several asset-realization processes underway in Kfar Baruch and Bat Shlomo. That could become helpful. But until money actually arrives, it should not be treated as cash. The disclosures say this directly: there is no certainty about the amount or timing of net proceeds. So this asset may help, but it cannot be the base case for funding the parent.

There is another layer of risk: FX. The portfolio is dollar-denominated, and the company explicitly states that a 5% move in the dollar against the shekel would generate roughly ILS 755 thousand of profit or loss. For a company of this size, with only a modest equity cushion, that is material. It also helps explain why even genuine operational progress at CDX did not translate into a clean-looking bottom line.

Outlook

Finding one: CDX’s PMA approval improved asset quality, but it did not improve parent solvency.

Finding two: The sharp reset in CardiacSense, EFA, and Nervio weakened diversification. From here, CDX carries most of the equity story.

Finding three: Recovery from the old loan may help, but it is not a reliable budget line.

Finding four: 2026 looks like a bridge year with a dual proof test. CDX must prove commercialization, and the parent must prove funding durability.

What Must Happen At CDX

The biggest issue over the next 2 to 4 quarters is whether CDX can turn FDA approval into real lab adoption. The report says that during 2026 the company plans a staged rollout to reference labs, commercial labs, and hospitals, alongside a post-approval study and continued clinical-data expansion. If that starts to generate adoption, broader coverage, and commercial partnerships, Merchavia will have a strong case that its core asset has moved from regulatory optionality to a real commercial platform. If not, the PMA approval will remain important, but not yet enough to produce accessible value upstream.

What Must Happen At The Parent

The parent needs to buy time without losing too much value through dilution. The market will watch three things: whether the controlling-shareholder facility is actually sufficient to bridge the next phase, whether any cash is realized from the old-loan recovery process, and whether the company can keep parent costs lean. If the answer on those points is only partial, the probability of another equity raise rises, and then even better news at CDX may still be offset by dilution at the listed-company layer.

What Could Improve The Picture

There is also a clear positive path. If CDX expands the number of labs and physicians using IsoPSA, if reimbursement breadth continues to improve, and if one of the other assets produces a commercial partnership, monetization event, or healthier financing round, the picture around Merchavia could improve quickly. Even a partial recovery from the historical loan could ease pressure at the parent, even if it does not solve everything.

What Could Break It

The most immediate risk is not scientific failure. It is costly or dilutive funding before CDX commercialization proves itself. If Merchavia needs another weakly priced capital raise, if the controlling-shareholder line is not enough, or if old-asset recoveries are delayed again, the whole picture changes. In that case, even investors who believe in the portfolio would have to acknowledge that the value is still sitting too far away from the public-shareholder layer.

Risks

Extreme Portfolio Concentration

More than 80% of the carrying value sits in CDX. That is extreme concentration for a holdco that only owns low-single-digit stakes to begin with. If CDX hits commercial delays, adoption friction, reimbursement issues, or weak financing terms, the hit will not stay isolated at one asset. It will flow directly into the entire Merchavia thesis.

Private Value Is Not Public Cash

Merchavia owns minority stakes in private companies. Even when value exists on paper, it is not liquid and can be constrained by contractual rights, investor preferences, and market conditions. So the gap between “a good asset” and “an asset that can finance the listed parent” remains large. That is a classic holdco risk, but here it is particularly sharp because the parent’s own cash balance is so thin.

FX And Marking Risk

The company measures the portfolio at fair value through profit and loss, with key holdings denominated in dollars and marked off private rounds and OPM-based valuation work. That means reported earnings can move materially even without a dramatic change in operating reality. The company itself estimates that a 5% move in the dollar creates roughly ILS 755 thousand of P&L impact. For an entity of this size, that is meaningful volatility.

Ongoing Funding Risk

The going concern note is not a technical footnote. It reflects a real issue: the parent’s own activity still does not generate meaningful income in the ordinary course of business, so continued existence depends on capital raising, asset realizations, broader distribution activity, or shareholder support. Any delay in those funding routes increases dilution risk.

Conclusions

End-2025 Merchavia looks better at the core-asset level and worse at the parent-company level. CDX is no longer just a regulatory hope, and that is a real improvement. But the parent’s cash remained thin, the rest of the portfolio weakened, and the company still depends on external funding to buy time.

Current thesis in one line: Merchavia is now mostly a leveraged public option on CDX commercialization, with the main bottleneck being whether the parent can survive without further dilution until that value starts to become accessible.

What changed versus the earlier view? First, CDX now has a real regulatory-commercial anchor, which clearly improves asset quality. Second, diversification weakened materially, especially after the sharp reset in CardiacSense. So the story improved at the main asset level while becoming riskier at the concentration and parent-funding levels.

The strongest counter-thesis: the market may be right to value Merchavia well above book, because if CDX’s 2026 rollout turns into real commercial traction, and if asset recoveries begin to bring in cash, the current parent liquidity squeeze may ultimately prove temporary rather than structural.

What could change the market’s interpretation over the short to medium term? Mainly three things: measurable IsoPSA lab adoption, actual use of the controlling-shareholder facility, and concrete receipts from the historical loan recovery path. Why this matters: in Merchavia’s case, the central question is still the gap between value created in the portfolio and value that can actually reach public shareholders.

Over the next 2 to 4 quarters, the thesis strengthens if CDX shows measurable commercial traction and the parent gets through the period without another weak capital raise. It weakens if Merchavia is forced into more dilution before commercialization is proven, or if the expected recovery from historical assets slips again.